Polycyclic aromatic compounds as anticancer agents: Evaluation of synthesis and in vitro cytotoxicity

Bandyopadhyay,Debasish; Granados,Jose  C.; Short,John  D.; Banik,Bimal  K.

doi:10.3892/ol.2011.436

Polycyclic aromatic compounds as anticancer agents: Evaluation of synthesis and in vitro cytotoxicity

Authors:
- Debasish Bandyopadhyay
- Jose C. Granados
- John D. Short
- Bimal K. Banik
View Affiliations

Affiliations: Department of Chemistry, The University of Texas-Pan American, Edinburg, Texas 78539, USA, University of Texas Health Science Center at San Antonio-Regional Academic Health Center, Medical Research Division, Edinburg, TX 78541, USA
Published online on: October 4, 2011 https://doi.org/10.3892/ol.2011.436
Pages: 45-49

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Polycyclic aromatic hydrocarbons (PAHs) are considered to be significant environmental carcinogens. Additionally, various planar ring systems are capable of intercalating with DNA, leading to a number of drugs that possess chemotherapeutic activity. In this study, three new polyaromatic compounds with a side chain were synthesized, and spectroscopic as well as elemental analyses were performed. The addition of the long chains to either chrysene or pyrene caused a red-shift in the spectral emission when compared to the corresponding polycyclic aromatic hydrocarbons itself. Furthermore, the cytotoxicity of the three novel polyaromatic compounds was evaluated in vitro in a panel of cultured mammalian cell lines. The pyrenyl ether demonstrated better cytotoxicity compared to cisplatin against colon (HT-29) as well as cervical (HeLa) cancer cell lines. In conclusion, three new compounds were synthesized and investigated in this study. This novel method is likely to play a role in other areas of research.

View Figures

View References

1	Banik BK and Becker FF: Synthesis, electrophilic substitution and structure-activity relationship studies of polycyclic aromatic compounds towards the development of anticancer agents. Curr Med Chem. 8:1513–1533. 2001. View Article : Google Scholar
2	Lerman LS: Structural considerations in interaction of DNA and acridines. J Mol Biol. 3:18–30. 1961. View Article : Google Scholar : PubMed/NCBI
3	Lerman LS: Structure of DNA-acridine complex. Proc Natl Acad Sci USA. 49:94–102. 1963. View Article : Google Scholar
4	Brana MF, Cacho M, Gradillas A, de Pascual-Teresa B and Ramos A: Intercalators as anticancer drugs. Curr Pharm Des. 7:1745–1780. 2001. View Article : Google Scholar : PubMed/NCBI
5	Martinez R and Chacon-Garcia L: The search of DNA- intercalators as antitumoral drugs: what it worked and what did not work. Curr Med Chem. 12:127–151. 2005. View Article : Google Scholar : PubMed/NCBI
6	Malonne H and Atassi G: DNA topoisomerase targeting drugs: mechanisms of action and perspectives. Anticancer Drugs. 8:811–822. 1997. View Article : Google Scholar : PubMed/NCBI
7	Banik BK and Becker FF: Polycyclic aromatic compounds as anticancer agents: structure-activity relationships of chrysene and pyrene derivatives. Bioorg Med Chem. 9:593–605. 2001. View Article : Google Scholar : PubMed/NCBI
8	Wunz TP, Craven MT, Karol MD, Hill GC and Remers WA: DNA-binding by antitumor anthracene-derivatives. J Med Chem. 33:1549–1553. 1990. View Article : Google Scholar : PubMed/NCBI
9	Iyengar BS, Dorr RT, Alberts DS, Solyom AM, Krutzsch M and Remers WA: 1,4-disubstituted anthracene antitumor agents. J Med Chem. 40:3734–3738. 1997. View Article : Google Scholar : PubMed/NCBI
10	Dorr RT, Liddil JD, Sami SM, Remers W, Hersh EM and Alberts DS: Preclinical antitumor activity of the azonafide series of anthracene-based DNA intercalators. Anticancer Drugs. 12:213–220. 2001. View Article : Google Scholar : PubMed/NCBI
11	Rescifina A, Chiacchio MA, Corsaro A, De Clercq E, Iannazzo D, Mastino A, Piperno A, Romeo G, Romeo R and Valveri V: Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators. J Med Chem. 49:709–715. 2006. View Article : Google Scholar : PubMed/NCBI
12	Kamal A, Ramesh G, Srinivas O and Ramulu P: Synthesis and antitumour activity of pyrene-linked pyrrolo [2,1-c][1,4]benzodiazepine hybrids. Bioorg Med Chem Lett. 14:471–474. 2004.PubMed/NCBI
13	Bair KW, Tuttle RL, Knick VC, Cory M and McKee DD: (1-Pyrenylmethyl) amino alcohols, a new class of antitumor DNA intercalators – discovery and initial amine side-chain structure activity studies. J Med Chem. 33:2385–2393. 1990.PubMed/NCBI
14	Bair KW, Andrews CW, Tuttle RL, Knick VC, Cory M and McKee DD: 2-[(arylmethyl)amino]-2-methyl-1,3-propanediol DNA intercalators – an examination of the effects of aromatic ring variation on antitumor-activity and DNA-binding. J Med Chem. 34:1983–1990. 1991.
15	Demeunynck M, Bailly C and Wilson WD: DNA and RNA Binders. Wiley-VCH. Weinheim: 2002. View Article : Google Scholar
16	De Vita VT, Hellman S and Rosenberg SA: Cancer: Principles and Practice of Oncology. 6th edition. Lippincott Williams and Wilkins; Philadelphia, PA: 2001
17	Lown JW: Anthracycline and anthraquinone anticancer agents: current status and recent developments. Pharmacol Ther. 60:185–214. 1993. View Article : Google Scholar : PubMed/NCBI
18	Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66. 2007. View Article : Google Scholar
19	Banik BK, Basu MK and Becker FF: Novel disubstituted chrysene as a potent agent against colon cancer. Oncol Lett. 1:1033–1035. 2010.PubMed/NCBI
20	Banik BK and Becker FF: Novel 6,12-disubstituted chrysene as potent anticancer agent: synthesis, in vitro and in vivo study. Eur J Med Chem. 45:4687–4691. 2010. View Article : Google Scholar : PubMed/NCBI
21	Banik BK, Mukhopadhyay C and Becker FF: Synthesis and biological evaluation of novel dibenzofluorene derivatives as anticancer agents. Oncol Lett. 1:309–311. 2010. View Article : Google Scholar : PubMed/NCBI
22	Banik BK, Samajdar S and Becker FF: Asymmetric synthesis of anticancer β-lactams via Staudinger reaction. Mol Med Reports. 3:319–321. 2010.
23	Banik BK and Becker FF: Selective anticancer activity of β-lactams derived from polyaromatic compound. Mol Med Reports. 3:315–316. 2010.
24	Banik BK, Banik I and Becker FF: Asymmetric synthesis of anticancer β-lactams via Staudinger reaction: utilization of chiral ketene from carbohydrate. Eur J Med Chem. 45:846–848. 2010.
25	Banik BK, Banik I and Becker FF: Stereocontrolled synthesis of anticancer β-lactams via the Staudinger reaction. Biorg Med Chem. 13:3611–3622. 2005.
26	Banik BK, Becker FF and Banik I: Synthesis of anticancer β-lactams: mechanism of action. Biorg Med Chem. 12:2523–2528. 2004.
27	Banik I, Becker FF and Banik BK: Stereoselective synthesis of β-lactams with polyaromatic imines: entry to new and novel anticancer agents. J Med Chem. 46:12–15. 2003.
28	Becker FF, Mukhopadhyay C, Hackfeld L, Banik I and Banik BK: Polycyclic aromatic compounds as anticancer agents: synthesis and biological evaluation of dibenzofluorene derivatives. Bioorg Med Chem. 8:2693–2699. 2000. View Article : Google Scholar : PubMed/NCBI
29	Becker FF and Banik BK: Polycyclic aromatic compounds as anticancer agents: synthesis and biological evaluation of some chrysene derivatives. Biorg Med Chem Lett. 8:2877–2880. 1998. View Article : Google Scholar : PubMed/NCBI
30	Vichai V and Kirtikara K: Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 1:1112–1116. 2006. View Article : Google Scholar : PubMed/NCBI
31	Búcsiová L, Hrdlovič P and Chmela S: Spectral characteristics of fluorescence probes based on pyrene in solution and in polymer matrices. J Photochem Photobiol A Chem. 143:59–68. 2001.
32	Hrdlovič P and Chmela S: Spectral characteristics of probes based on ionic derivatives of pyrene in polar polymer matrices. J Photochem Photobiol A Chem. 118:137–142. 1998.
33	Spiro M, Vigny P and Hodgson RM: Fluorescence spectral studies on the metabolic activation of chrysene by hamster embryo cells. Carcinogenesis. 3:1491–1493. 1982. View Article : Google Scholar : PubMed/NCBI
34	Ohara K, Smietana M, Restouin A, Mollard S, Borg J, Collette Y and Vasseur J: Amine-guanidine switch: a promising approach to improve DNA binding and antiproliferative activities. J Med Chem. 50:6465–6475. 2007. View Article : Google Scholar : PubMed/NCBI
35	Landis-Piwowar KR, Chen D, Cui QC, Minic V, Becker FF, Banik BK and Dou QP: Apoptotic-inducing activity of novel polyaromatic compounds in human leukemic cells. Int J Mol Med. 17:931–935. 2006.PubMed/NCBI